Beschreibung
Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.
Mechanismus
Levodopa is converted to dopamine and acts on striatal D2 receptors to improve Parkinsonism; quetiapine blocks D2 receptors, directly countering this therapeutic effect.
Klinische Bedeutung
Significant worsening of motor function (rigidity, bradykinesia, tremor) is expected when typical or atypical antipsychotics (except clozapine and pimavanserin) are used in Parkinson's disease.
Maßnahmen
Avoid dopamine-blocking antipsychotics in Parkinson's disease; use clozapine or pimavanserin (low D2 affinity) for psychosis management.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.